Plain-English translation of NCT05018299 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied whether , an antibody that targets inflammation in the body, could help adults with severe asthma breathe better and have better symptom control. About 20 adults with severe asthma received either the medication or a placebo as intravenous infusions over several weeks. Researchers measured how well the treatment worked and whether it was safe.
Severe asthma is hard to control even with standard medicines, and many patients struggle with ongoing symptoms and breathing problems. This medication was being tested to see if targeting a specific inflammatory pathway could offer a new treatment option for people whose asthma doesn't respond well to current therapies.
Participants attended a 4-week screening period to confirm they had severe asthma with the right type of inflammation. Those who qualified received four intravenous infusions of either the medication or placebo (each infusion took about 1 hour). Throughout the study, participants had multiple clinic visits where doctors measured their lung function, checked their asthma symptoms, and took blood and sputum samples to evaluate safety and how the body responded to the treatment.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Taiwan